---
document_datetime: 2025-12-02 05:49:15
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/micardis.html
document_name: micardis.html
version: success
processing_time: 0.1411091
conversion_datetime: 2025-12-28 19:35:18.714835
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Micardis

[RSS](/en/individual-human-medicine.xml/65413)

##### Authorised

This medicine is authorised for use in the European Union

telmisartan Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Micardis](#news-on)
- [More information on Micardis](#more-information-on-micardis-433)
- [More information on Micardis](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).

Expand section

Collapse section

## What is Micardis?

Micardis is a medicine that contains the active substance telmisartan. It is available as tablets (20, 40 and 80 mg).

## What is Micardis used for?

Micardis is used to treat essential hypertension (high blood pressure) in adults. 'Essential' means that the hypertension has no obvious cause.

Micardis is also used to prevent cardiovascular problems (problems with the heart and blood vessels) such as heart attacks or strokes. It is used in patients who have had problems due to blood clots in the past (such as heart disease, a stroke or artery disease) or who have type-2 diabetes that has damaged an organ (such as the eyes, heart or kidneys).

The medicine can only be obtained with a prescription.

## How is Micardis used?

For the treatment of essential hypertension, the usual recommended dose of Micardis is 40 mg once a day, but some patients may benefit from using 20 mg once a day. If the target blood pressure is not reached, the dose can be increased to 80 mg, or another medicine for hypertension can be added, such as hydrochlorothiazide.

For the prevention of cardiovascular problems, the recommended dose is 80 mg once a day. The doctor should monitor the patient's blood pressure closely when starting Micardis, and may decide to adjust the patient's blood-pressure-lowering medication. Patients with severely reduced kidney function should receive a lower starting dose of 20 mg once a day. Patients with mild or moderately reduced liver function should not receive doses higher than 40 mg a day.

## How does Micardis work?

The active substance in Micardis, telmisartan, is an 'angiotensin-II-receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II. Angiotensin II is a powerful vasoconstrictor (a substance that narrows blood vessels). By blocking the receptors to which angiotensin II normally attaches, telmisartan stops the hormone having an effect, allowing the blood vessels to widen. This allows the blood pressure to drop, reducing the risks associated with high blood pressure, such as having a heart attack or stroke. It also allows the heart to pump blood more easily, which can help to reduce the risk of future cardiovascular problems.

## How has Micardis been studied?

For the treatment of essential hypertension, Micardis has been studied in 2,647 patients who took Micardis either alone or in combination with hydrochlorothiazide. Various doses of Micardis were compared with placebo (a dummy treatment) and with other medicines for hypertension (atenolol, lisinopril, enalapril and amlodipine). The main measure of effectiveness was the reduction in diastolic blood pressure (the blood pressure measured between two heartbeats).

For the prevention of cardiovascular problems, 80 mg Micardis once a day has been studied in one main study involving almost 26,000 patients aged 55 years or over who had heart or artery disease, had had a stroke, or had diabetes and were at high risk of cardiovascular problems. Micardis was compared with ramipril (another medicine to prevent cardiovascular problems), and with the combination of both medicines. The main measure of effectiveness was the reduction in the number of patients who died or were admitted to hospital, or who had a heart attack or stroke. The patients were followed up for an average of four and a half years.

## What benefit has Micardis shown during the studies?

In the treatment of essential hypertension, Micardis was more effective than placebo at reducing diastolic blood pressure and had similar effects to the other medicines for hypertension.

In the prevention of cardiovascular problems, Micardis had a similar effect to ramipril, with around 17% of patients dying, being admitted to hospital because of cardiovascular problems, or having a heart attack or stroke. The combination of the two medicines was no more effective than either medicine taken alone and was linked to an increased risk of side effects.

## What is the risk associated with Micardis?

Side effects with Micardis are not common. However, the following side effects are seen in between 1 and 10 patients in 1,000: upper-respiratory-tract infection (colds) including inflammation of the throat and sinuses, urinary-tract infection (infection of the structures that carry urine) including bladder infection, anaemia (low red-blood-cell counts), hyperkalaemia (high blood potassium levels), depression, insomnia (difficulty sleeping), syncope (fainting), vertigo (a spinning sensation), bradycardia (slow heart rate), hypotension (low blood pressure), dyspnoea (difficulty breathing), cough, abdominal pain (stomach ache), diarrhoea, dyspepsia (heartburn), flatulence (gas), vomiting, hyperhidrosis (excessive sweating), pruritus (itching), rash, myalgia (muscle pain), back pain, muscle spasms, renal impairment (reduced kidney function) including sudden kidney failure, chest pain, asthenia (weakness) and increased blood levels of creatinine (a marker of muscle breakdown). Hypotension may be more common in patients receiving Micardis to prevent cardiovascular problems. For the full list of all side effects reported with Micardis, see the package leaflet.

Micardis must not be used in women who are more than three months pregnant. Its use during the first three months of pregnancy is not recommended. Micardis must not be used in people who have severe liver problems or bile problems. In patients with type 2 diabetes or in patients with moderate or severe kidney impairment, Micardis must also not be used in combination with aliskiren-containing medicines (also used to treat essential hypertension). For the full list of restrictions, see the package leaflet.

## Why has Micardis been approved?

The CHMP decided that Micardis's benefits are greater than its risks and recommended that it be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of Micardis?

A risk management plan has been developed to ensure that Micardis is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Micardis, including the appropriate precautions to be followed by healthcare professionals and patients.

## Other information about Micardis

The European Commission granted a marketing authorisation valid throughout the European Union for Micardis on 16 December 1998.

For more information about treatment with Micardis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Micardis : EPAR - Summary for the public

English (EN) (77.12 KB - PDF)

**First published:** 06/05/2009

**Last updated:** 06/11/2015

[View](/en/documents/overview/micardis-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-391)

български (BG) (109.19 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

06/11/2015

[View](/bg/documents/overview/micardis-epar-summary-public_bg.pdf)

español (ES) (84.29 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

06/11/2015

[View](/es/documents/overview/micardis-epar-summary-public_es.pdf)

čeština (CS) (106.03 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

06/11/2015

[View](/cs/documents/overview/micardis-epar-summary-public_cs.pdf)

dansk (DA) (83.11 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

06/11/2015

[View](/da/documents/overview/micardis-epar-summary-public_da.pdf)

Deutsch (DE) (86 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

06/11/2015

[View](/de/documents/overview/micardis-epar-summary-public_de.pdf)

eesti keel (ET) (82.54 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

06/11/2015

[View](/et/documents/overview/micardis-epar-summary-public_et.pdf)

ελληνικά (EL) (112.01 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

06/11/2015

[View](/el/documents/overview/micardis-epar-summary-public_el.pdf)

français (FR) (85.15 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

06/11/2015

[View](/fr/documents/overview/micardis-epar-summary-public_fr.pdf)

hrvatski (HR) (101.33 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

06/11/2015

[View](/hr/documents/overview/micardis-epar-summary-public_hr.pdf)

italiano (IT) (83.52 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

06/11/2015

[View](/it/documents/overview/micardis-epar-summary-public_it.pdf)

latviešu valoda (LV) (87.73 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

06/11/2015

[View](/lv/documents/overview/micardis-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (84.77 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

06/11/2015

[View](/lt/documents/overview/micardis-epar-summary-public_lt.pdf)

magyar (HU) (100.91 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

06/11/2015

[View](/hu/documents/overview/micardis-epar-summary-public_hu.pdf)

Malti (MT) (85.98 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

06/11/2015

[View](/mt/documents/overview/micardis-epar-summary-public_mt.pdf)

Nederlands (NL) (117.14 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

06/11/2015

[View](/nl/documents/overview/micardis-epar-summary-public_nl.pdf)

polski (PL) (87.93 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

06/11/2015

[View](/pl/documents/overview/micardis-epar-summary-public_pl.pdf)

português (PT) (57.5 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

06/11/2015

[View](/pt/documents/overview/micardis-epar-summary-public_pt.pdf)

română (RO) (83.8 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

06/11/2015

[View](/ro/documents/overview/micardis-epar-summary-public_ro.pdf)

slovenčina (SK) (84.59 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

06/11/2015

[View](/sk/documents/overview/micardis-epar-summary-public_sk.pdf)

slovenščina (SL) (81.79 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

06/11/2015

[View](/sl/documents/overview/micardis-epar-summary-public_sl.pdf)

Suomi (FI) (82.63 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

06/11/2015

[View](/fi/documents/overview/micardis-epar-summary-public_fi.pdf)

svenska (SV) (57.26 KB - PDF)

**First published:**

06/05/2009

**Last updated:**

06/11/2015

[View](/sv/documents/overview/micardis-epar-summary-public_sv.pdf)

Micardis : EPAR - Risk management plan

English (EN) (1.2 MB - PDF)

**First published:** 30/09/2025

[View](/en/documents/rmp/micardis-epar-risk-management-plan_en.pdf)

## Product information

Micardis : EPAR - Product information

English (EN) (674.11 KB - PDF)

**First published:** 23/01/2007

**Last updated:** 23/04/2025

[View](/en/documents/product-information/micardis-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-3)

български (BG) (803.4 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/04/2025

[View](/bg/documents/product-information/micardis-epar-product-information_bg.pdf)

español (ES) (699.72 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/04/2025

[View](/es/documents/product-information/micardis-epar-product-information_es.pdf)

čeština (CS) (783.61 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/04/2025

[View](/cs/documents/product-information/micardis-epar-product-information_cs.pdf)

dansk (DA) (688.65 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/04/2025

[View](/da/documents/product-information/micardis-epar-product-information_da.pdf)

Deutsch (DE) (699.99 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/04/2025

[View](/de/documents/product-information/micardis-epar-product-information_de.pdf)

eesti keel (ET) (684.93 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/04/2025

[View](/et/documents/product-information/micardis-epar-product-information_et.pdf)

ελληνικά (EL) (809.84 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/04/2025

[View](/el/documents/product-information/micardis-epar-product-information_el.pdf)

français (FR) (774.5 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/04/2025

[View](/fr/documents/product-information/micardis-epar-product-information_fr.pdf)

hrvatski (HR) (767.26 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/04/2025

[View](/hr/documents/product-information/micardis-epar-product-information_hr.pdf)

íslenska (IS) (734.62 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/04/2025

[View](/is/documents/product-information/micardis-epar-product-information_is.pdf)

italiano (IT) (738.59 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/04/2025

[View](/it/documents/product-information/micardis-epar-product-information_it.pdf)

latviešu valoda (LV) (736.98 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/04/2025

[View](/lv/documents/product-information/micardis-epar-product-information_lv.pdf)

lietuvių kalba (LT) (774.04 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/04/2025

[View](/lt/documents/product-information/micardis-epar-product-information_lt.pdf)

magyar (HU) (763.66 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/04/2025

[View](/hu/documents/product-information/micardis-epar-product-information_hu.pdf)

Malti (MT) (846.4 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/04/2025

[View](/mt/documents/product-information/micardis-epar-product-information_mt.pdf)

Nederlands (NL) (728.59 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/04/2025

[View](/nl/documents/product-information/micardis-epar-product-information_nl.pdf)

norsk (NO) (675.06 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/04/2025

[View](/no/documents/product-information/micardis-epar-product-information_no.pdf)

polski (PL) (801.54 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/04/2025

[View](/pl/documents/product-information/micardis-epar-product-information_pl.pdf)

português (PT) (694.95 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/04/2025

[View](/pt/documents/product-information/micardis-epar-product-information_pt.pdf)

română (RO) (816.55 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/04/2025

[View](/ro/documents/product-information/micardis-epar-product-information_ro.pdf)

slovenčina (SK) (808.23 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/04/2025

[View](/sk/documents/product-information/micardis-epar-product-information_sk.pdf)

slovenščina (SL) (764.19 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/04/2025

[View](/sl/documents/product-information/micardis-epar-product-information_sl.pdf)

Suomi (FI) (679.73 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/04/2025

[View](/fi/documents/product-information/micardis-epar-product-information_fi.pdf)

svenska (SV) (671.48 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/04/2025

[View](/sv/documents/product-information/micardis-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000242970 03/04/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Micardis : EPAR - All Authorised presentations

English (EN) (30.75 KB - PDF)

**First published:** 23/01/2007

**Last updated:** 07/09/2018

[View](/en/documents/all-authorised-presentations/micardis-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-712)

български (BG) (27.09 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

07/09/2018

[View](/bg/documents/all-authorised-presentations/micardis-epar-all-authorised-presentations_bg.pdf)

español (ES) (23.42 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

07/09/2018

[View](/es/documents/all-authorised-presentations/micardis-epar-all-authorised-presentations_es.pdf)

čeština (CS) (25.56 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

07/09/2018

[View](/cs/documents/all-authorised-presentations/micardis-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (24.39 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

07/09/2018

[View](/da/documents/all-authorised-presentations/micardis-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (24.99 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

07/09/2018

[View](/de/documents/all-authorised-presentations/micardis-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (29.83 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

07/09/2018

[View](/et/documents/all-authorised-presentations/micardis-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (26.1 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

07/09/2018

[View](/el/documents/all-authorised-presentations/micardis-epar-all-authorised-presentations_el.pdf)

français (FR) (23.34 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

07/09/2018

[View](/fr/documents/all-authorised-presentations/micardis-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (24.07 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

07/09/2018

[View](/hr/documents/all-authorised-presentations/micardis-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (30.56 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

07/09/2018

[View](/is/documents/all-authorised-presentations/micardis-epar-all-authorised-presentations_is.pdf)

italiano (IT) (23.36 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

07/09/2018

[View](/it/documents/all-authorised-presentations/micardis-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (36.43 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

07/09/2018

[View](/lv/documents/all-authorised-presentations/micardis-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (32.1 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

07/09/2018

[View](/lt/documents/all-authorised-presentations/micardis-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (26.32 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

07/09/2018

[View](/hu/documents/all-authorised-presentations/micardis-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (24.8 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

07/09/2018

[View](/mt/documents/all-authorised-presentations/micardis-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (23.78 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

07/09/2018

[View](/nl/documents/all-authorised-presentations/micardis-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (23.98 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

07/09/2018

[View](/no/documents/all-authorised-presentations/micardis-epar-all-authorised-presentations_no.pdf)

polski (PL) (24.35 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

07/09/2018

[View](/pl/documents/all-authorised-presentations/micardis-epar-all-authorised-presentations_pl.pdf)

português (PT) (23.86 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

07/09/2018

[View](/pt/documents/all-authorised-presentations/micardis-epar-all-authorised-presentations_pt.pdf)

română (RO) (23.56 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

07/09/2018

[View](/ro/documents/all-authorised-presentations/micardis-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (25.5 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

07/09/2018

[View](/sk/documents/all-authorised-presentations/micardis-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (24.87 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

07/09/2018

[View](/sl/documents/all-authorised-presentations/micardis-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (30.54 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

07/09/2018

[View](/fi/documents/all-authorised-presentations/micardis-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (23.87 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

07/09/2018

[View](/sv/documents/all-authorised-presentations/micardis-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Micardis Active substance telmisartan International non-proprietary name (INN) or common name telmisartan Therapeutic area (MeSH) Hypertension Anatomical therapeutic chemical (ATC) code C09CA07

### Pharmacotherapeutic group

Angiotensin II antagonists, plain

### Therapeutic indication

**Hypertension**

Treatment of essential hypertension in adults.

**Cardiovascular prevention**

Reduction of cardiovascular morbidity in patients with:

- manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;
- type-2 diabetes mellitus with documented target-organ damage.

## Authorisation details

EMA product number EMEA/H/C/000209 Marketing authorisation holder

Boehringer Ingelheim International GmbH

Bingerstr. 173

Marketing authorisation issued 16/12/1998 Revision 31

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Micardis : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (147.17 KB - PDF)

**First published:** 23/04/2025

[View](/en/documents/procedural-steps-after/micardis-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Micardis : EPAR - Procedural steps taken before authorisation

English (EN) (121.83 KB - PDF)

**First published:** 26/02/2025

[View](/en/documents/procedural-steps-after/micardis-epar-procedural-steps-taken-authorisation_en.pdf)

Micardis : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (289.08 KB - PDF)

**First published:** 25/06/2009

**Last updated:** 23/04/2025

[View](/en/documents/procedural-steps-after/micardis-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Micardis-H-C-209-A31-0099 : EPAR - Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommend...

English (EN) (48.81 KB - PDF)

**First published:** 25/09/2014

**Last updated:** 25/09/2014

[View](/en/documents/scientific-conclusion/micardis-h-c-209-a31-0099-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommend_en.pdf)

[Other languages (22)](#file-language-dropdown-564)

български (BG) (87.49 KB - PDF)

**First published:**

25/09/2014

**Last updated:**

25/09/2014

[View](/bg/documents/scientific-conclusion/micardis-h-c-209-a31-0099-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommend_bg.pdf)

español (ES) (50.51 KB - PDF)

**First published:**

25/09/2014

**Last updated:**

25/09/2014

[View](/es/documents/scientific-conclusion/micardis-h-c-209-a31-0099-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommend_es.pdf)

čeština (CS) (82.81 KB - PDF)

**First published:**

25/09/2014

**Last updated:**

25/09/2014

[View](/cs/documents/scientific-conclusion/micardis-h-c-209-a31-0099-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommend_cs.pdf)

dansk (DA) (49.01 KB - PDF)

**First published:**

25/09/2014

**Last updated:**

25/09/2014

[View](/da/documents/scientific-conclusion/micardis-h-c-209-a31-0099-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommend_da.pdf)

Deutsch (DE) (53.54 KB - PDF)

**First published:**

25/09/2014

**Last updated:**

25/09/2014

[View](/de/documents/scientific-conclusion/micardis-h-c-209-a31-0099-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommend_de.pdf)

eesti keel (ET) (50.6 KB - PDF)

**First published:**

25/09/2014

**Last updated:**

25/09/2014

[View](/et/documents/scientific-conclusion/micardis-h-c-209-a31-0099-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommend_et.pdf)

ελληνικά (EL) (89.54 KB - PDF)

**First published:**

25/09/2014

**Last updated:**

25/09/2014

[View](/el/documents/scientific-conclusion/micardis-h-c-209-a31-0099-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommend_el.pdf)

français (FR) (51.91 KB - PDF)

**First published:**

25/09/2014

**Last updated:**

25/09/2014

[View](/fr/documents/scientific-conclusion/micardis-h-c-209-a31-0099-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommend_fr.pdf)

hrvatski (HR) (80.12 KB - PDF)

**First published:**

25/09/2014

**Last updated:**

25/09/2014

[View](/hr/documents/scientific-conclusion/micardis-h-c-209-a31-0099-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommend_hr.pdf)

italiano (IT) (51.13 KB - PDF)

**First published:**

25/09/2014

**Last updated:**

25/09/2014

[View](/it/documents/scientific-conclusion/micardis-h-c-209-a31-0099-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommend_it.pdf)

latviešu valoda (LV) (81.63 KB - PDF)

**First published:**

25/09/2014

**Last updated:**

25/09/2014

[View](/lv/documents/scientific-conclusion/micardis-h-c-209-a31-0099-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommend_lv.pdf)

lietuvių kalba (LT) (82.54 KB - PDF)

**First published:**

25/09/2014

**Last updated:**

25/09/2014

[View](/lt/documents/scientific-conclusion/micardis-h-c-209-a31-0099-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommend_lt.pdf)

magyar (HU) (68.7 KB - PDF)

**First published:**

25/09/2014

**Last updated:**

25/09/2014

[View](/hu/documents/scientific-conclusion/micardis-h-c-209-a31-0099-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommend_hu.pdf)

Malti (MT) (84.23 KB - PDF)

**First published:**

25/09/2014

**Last updated:**

25/09/2014

[View](/mt/documents/scientific-conclusion/micardis-h-c-209-a31-0099-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommend_mt.pdf)

Nederlands (NL) (49.82 KB - PDF)

**First published:**

25/09/2014

**Last updated:**

25/09/2014

[View](/nl/documents/scientific-conclusion/micardis-h-c-209-a31-0099-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommend_nl.pdf)

polski (PL) (83.62 KB - PDF)

**First published:**

25/09/2014

**Last updated:**

25/09/2014

[View](/pl/documents/scientific-conclusion/micardis-h-c-209-a31-0099-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommend_pl.pdf)

português (PT) (49.74 KB - PDF)

**First published:**

25/09/2014

**Last updated:**

25/09/2014

[View](/pt/documents/scientific-conclusion/micardis-h-c-209-a31-0099-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommend_pt.pdf)

română (RO) (88.19 KB - PDF)

**First published:**

25/09/2014

**Last updated:**

25/09/2014

[View](/ro/documents/scientific-conclusion/micardis-h-c-209-a31-0099-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommend_ro.pdf)

slovenčina (SK) (81.5 KB - PDF)

**First published:**

25/09/2014

**Last updated:**

25/09/2014

[View](/sk/documents/scientific-conclusion/micardis-h-c-209-a31-0099-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommend_sk.pdf)

slovenščina (SL) (79.79 KB - PDF)

**First published:**

25/09/2014

**Last updated:**

25/09/2014

[View](/sl/documents/scientific-conclusion/micardis-h-c-209-a31-0099-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommend_sl.pdf)

Suomi (FI) (49.15 KB - PDF)

**First published:**

25/09/2014

**Last updated:**

25/09/2014

[View](/fi/documents/scientific-conclusion/micardis-h-c-209-a31-0099-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommend_fi.pdf)

svenska (SV) (50.18 KB - PDF)

**First published:**

25/09/2014

**Last updated:**

25/09/2014

[View](/sv/documents/scientific-conclusion/micardis-h-c-209-a31-0099-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommend_sv.pdf)

Micardis-H-C-209-A31-0099 : EPAR - Assessment Report - Article 31

Adopted

Reference Number: EMA/PRAC/294920/2014

English (EN) (301.42 KB - PDF)

**First published:** 25/09/2014

**Last updated:** 25/09/2014

[View](/en/documents/variation-report/micardis-h-c-209-a31-0099-epar-assessment-report-article-31_en.pdf)

CHMP post-authorisation summary of positive opinion for Micardis

Adopted

Reference Number: EMA/CHMP/261191/2013

English (EN) (67.42 KB - PDF)

**First published:** 26/04/2013

**Last updated:** 26/04/2013

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-micardis_en.pdf)

Micardis-H-C-209-WS-0254 : EPAR -  Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/549534/2012

English (EN) (547.43 KB - PDF)

**First published:** 27/03/2013

**Last updated:** 27/03/2013

[View](/en/documents/variation-report/micardis-h-c-209-ws-0254-epar-assessment-report-variation_en.pdf)

Micardis-H-C-209-II-0073 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/768468/2009

English (EN) (1.1 MB - PDF)

**First published:** 08/02/2010

**Last updated:** 08/02/2010

[View](/en/documents/variation-report/micardis-h-c-209-ii-0073-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Micardis on 22 October 2009

Adopted

Reference Number: EMEA/CHMP/676934/2009

English (EN) (30.26 KB - PDF)

**First published:** 22/10/2009

**Last updated:** 22/10/2009

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-micardis-22-october-2009_en.pdf)

Micardis : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (104.66 KB - PDF)

**First published:** 10/07/2006

**Last updated:** 10/07/2006

[View](/en/documents/steps-after-cutoff/micardis-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Micardis : EPAR - Procedural steps taken before authorisation (archive)

English (EN) (84.5 KB - PDF)

**First published:** 10/07/2006

**Last updated:** 26/02/2025

[View](/en/documents/procedural-steps/micardis-epar-procedural-steps-taken-authorisation-archive_en.pdf)

Micardis : EPAR - Scientific Discussion

English (EN) (239.29 KB - PDF)

**First published:** 10/07/2006

**Last updated:** 10/07/2006

[View](/en/documents/scientific-discussion/micardis-epar-scientific-discussion_en.pdf)

#### News on Micardis

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2013](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-may-2013) 17/05/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2013) 26/04/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 October 2011](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-october-2011) 21/10/2011

[European Medicines Agency concludes that benefit-risk balance of angiotensin-II-receptor antagonists remains positive](/en/news/european-medicines-agency-concludes-benefit-risk-balance-angiotensin-ii-receptor-antagonists-remains-positive) 20/10/2011

[European Medicines Agency recommendation on use of angiotensin-II-receptor antagonists during pregnancy](/en/news/european-medicines-agency-recommendation-use-angiotensin-ii-receptor-antagonists-during-pregnancy) 24/04/2008

#### More information on Micardis

- [Renin-angiotensin-system (RAS)-acting agents: Article-31 referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)

Questions and answers on the review of angiotensin-II-receptor antagonists and the risk of cancer

Reference Number: EMA/CHMP/834168/2011

English (EN) (511.41 KB - PDF)

**First published:** 20/10/2011

**Last updated:** 11/05/2017

[View](/en/documents/opinion-any-scientific-matter/questions-answers-review-angiotensin-ii-receptor-antagonists-risk-cancer_en.pdf)

#### More information on Micardis

- [Renin-angiotensin-system (RAS)-acting agents - referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 30/09/2025

## Share this page

[Back to top](#main-content)